OINDPnews


H&T Presspart Low GWP Banner

Medical

Sumatriptan nasal spray shortage expected to be resolved by February 2017

According to an FDA drug shortages report, the US shortage of sumatriptan nasal spray due to a shortage of active ingredient that was first reported in November 2015 should be completely resolved by February 2017. At this time, both GlaxoSmithKline and Sandoz are reported to have 5 mg/spray versions of the nasal spray available, and GSK has the 20 mg product … [Read more...] about Sumatriptan nasal spray shortage expected to be resolved by February 2017

Positive Phase 2 results for Patara’s inhaled treatment for chronic cough in IPF patients

Patara Pharma has announced Phase 2 results for its PA101 inhaled treatment for refractory chronic cough in patients with idiopathic pulmonary fibrosis (IPF) showing that patients receiving PA101 experienced a statistically significant reduction in cough frequency after 14 days compared to patients receiving a placebo. PA101 is delivered via the PARI eFlow nebulizer … [Read more...] about Positive Phase 2 results for Patara’s inhaled treatment for chronic cough in IPF patients

Flutiform fails to meet primary endpoint in Phase 3 trial for COPD

According to Vectura, Mundipharma's Phase 3 trial of the flutiform fluticasone/formoterol MDI failed to demonstrate statistically significant superiority compared to formoterol alone in reducing moderate and severe COPD exacerbations. Mundipharma had planned to seek approval from European regulators to market flutiform for the treatment of COPD but will now put off … [Read more...] about Flutiform fails to meet primary endpoint in Phase 3 trial for COPD

Paradigm Biopharmaceuticals completes Phase 1 trial of pentosan polysulfate sodium nasal spray

Paradigm Biopharmaceuticals has announced the completion of a Phase 1 clinical trial of its Rhinosul pentosan polysulfate sodium (PPS) nasal spray for allergic rhinitis. Paradigm said that none of the 18 healthy volunteers involved in the study experienced any significant adverse effects and that it anticipates the final report in October 2016. The company also … [Read more...] about Paradigm Biopharmaceuticals completes Phase 1 trial of pentosan polysulfate sodium nasal spray

AstraZeneca announces positive results from two Symbicort studies

AstraZeneca has announced top-line results from the Phase 3 RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) and CHASE 3 (ChildHood Asthma Safety and Efficacy) studies of the Symbicort budesonide/formoterol fumarate MDI showing that Symbicort met the primary endpoints in both studies. The RISE study compared twice daily Symbicort MDI … [Read more...] about AstraZeneca announces positive results from two Symbicort studies

Windtree gets $2.6 million for Phase 2b trial of Aerosurf

Windtree Therapeutics has received $1 million from a Phase 2 Small Business Innovation Research Grant (SBIR) worth up to $2.6 million for a Phase 2b trial of its Aerosurf aerosolized KL4 surfactant in premature infants with respiratory distress syndrome (RDS) who are receiving nasal continuous positive airway pressure (nCPAP). The company previously received a … [Read more...] about Windtree gets $2.6 million for Phase 2b trial of Aerosurf

Sunovion announces results of long-term safety study of glycopyrrolate inhalation solution

Sunovion has announced results from the Phase 3 GOLDEN-5 48-week safety study of SUN-101 glycopyrrolate inhalation solution in patients with moderate-to-very severe COPD. According to the company, the data show that SUN-101 was well tolerated, and the incidence of adverse events was similar to that of the active comparator, Spiriva Handihaler. The study enrolled 1,087 … [Read more...] about Sunovion announces results of long-term safety study of glycopyrrolate inhalation solution

McMaster researchers developing intranasal vaccine against chlamydia

Researchers at the Michael G. DeGroote Institute for Infectious Disease Research at McMaster University have published an article in the journal Vaccine describing promising results from a study of their intranasal BD584 chlamydial antigen against Chlamydia trachomatis, which can cause eye infections called trachoma that may result in blindness and can also cause … [Read more...] about McMaster researchers developing intranasal vaccine against chlamydia